Oncology Clinical Trials covers how to formulate a study question, selecting a study population, study design of Phase I, II, and III trials, toxicity monitoring, data analysis and reporting, use of genomics, cost-effectiveness analysis, systemic review and meta-analysis, and many other issues. Many examples of real-life flaws in clinical trials that have been reported in the literature are included throughout. The book discusses clinical trials from start to finish focusing on real-life examples in the development, design and analysis of clinical trials.
Oncology Clinical Trials features:Susan Halabi, PhD is the James B. Duke Distinguished Professor of Biostatistics and Bioinformatics and Co-Chief of the Division of Biostatistics in the Department of Biostatistics and Bioinformatics at Duke University Medical Center. For more than twenty-five years, she has been a leading authority in the design and analysis of oncology clinical trials. Dr. Halabi develops innovative statistical methods for clinical research, including novel variable selection techniques for biomarkers and high-dimensional data. Dr. Halabi is a past president of the Society for Clinical Trials and a former member of the FDA Oncology Drugs Advisory Committee. She is the recipient of several prestigious awards and is a Fellow of the Society for Clinical Trials, the American Statistical Association, and the American Society for Clinical Oncology.
William Kevin Kelly, DO, is Professor of Medical Oncology and Urology at Thomas Jefferson University. He currently serves as the Chair of the Department of Medical Oncology at Thomas Jefferson University and research advisor to the Cancer Center Director at the Sidney Cancer Comprehensive Cancer Center. He has also served in many leadership roles in the National Clinical Trials Network and was a member of the FDAs Oncology Drug Advisor Committee. His expertise is in drug and biomarker development and trial design/implementation in prostate and bladder cancer. He has been instrumental in defining the use of many novel therapies and biomarkers in patients with prostate and bladder cancer for all stages of these diseases.
Richard L. Schilsky, MD, Profesor of Medicine, University of Chicago, Chairman, Cancer and Leukemia Group B, ASCO President 2008-2009